Stem cell transplant in MF: it’s time to personalize

Slides:



Advertisements
Similar presentations
Tiziano Barbui MD Ospedale Papa Giovanni XXIII Bergamo, Italy
Advertisements

Hematology The Study of Blood Blood contains cells, proteins, and sugars Red blood cells transport oxygen- erythrocytes White blood cells are part of the.
What about stem cell transplantation? Dr Catherine Flynn Consultant Haematologist St James’s Hospital 17/06/2011.
Risk Stratification of Patients with Myelofibrosis and the Role of Transplant Alessandro M. Vannucchi Section of Hematology, University of Florence, Italy.
Hematocrit The ratio of blood cells to total blood volume, normally (men) and 0, (women)
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Pei Lin Professor of Pathology Department of Hematopathology
Good morning… My presentation is about Calreticulin and PMF
University Hamburg Medical Center Dept of Stem Cell Transplantation
Myelodysplastic syndrome(MDS)
Harrison CN et al. Proc ASH 2015;Abstract 59.
Ruxolitinib + Azacitidine in Newly Diagnosed or R/R, Intermediate- or High-Risk Myelofibrosis New Findings in Hematology: Independent Conference Coverage.
New Findings in Hematology: Independent Conference Coverage
MBL: mostly benign lymphocytes, but…
Patient A.
Program Goals Case 1: Woman With MDS Risk: Cytogenetic Subgroups.
Chronic Myeloproliferative Neoplasms (MPN) Ph-negative
Gupta V, Tallman MS, Weisdorf DJ
Prognostic factors for thrombosis and survival in PV, revisited
Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.
How to Treat MDS without Stem Cell Transplantation
Whom should you refer for allogeneic stem cell transplantation?
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program by Michael.
Mutagenic potential of temozolomide in bone marrow cells in vivo
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance by Elisabetta Antonioli, Paola Guglielmelli,
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
Full hematopoietic engraftment after allogeneic bone marrow transplantation without cytoreduction in a child with severe combined immunodeficiency by Ronald.
Vikas Gupta, Jason Gotlib, Jerald P. Radich, Nicolaus M
Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor Program  John P. Miller, Elizabeth H. Perry, Thomas H.
281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy    Molecular Therapy  Volume.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
ROCK and Rho(ll) in bone marrow
Allogeneic Stem Cell Transplantation in Myelofibrosis
Future Directions in Myelofibrosis: Implications of Emerging Approaches.
Dynamic of Bone Marrow Fibrosis Regression Predicts Survival after Allogeneic Stem Cell Transplantation for Myelofibrosis  Nicolaus Kröger, Tatjana Zabelina,
Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell.
Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation  Mats Remberger, Emma.
Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.
Sabina Kersting, Leo F. Verdonck 
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation  Gita Thanarajasingam, Haesook T. Kim,
Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation  Bipin N. Savani, Theresa Donohue,
Leukemia case Maha Areej Faten.
A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model  Justin N. Baker,
MicroRNA Methylation Profile Has Prognosis Impact in Acute Lymphoblastic Leukemia Patients Undergoing Stem Cell Transplantation  Vanesa Martín-Palanco,
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase.
Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Normal Immunologic Response to a Neoantigen, Bacteriophage ΦX-174, in Baboons With Long-Term Lymphohematopoietic Reconstitution From Highly Purified CD34+
by Geling Li, Emily Waite, and Julie Wolfson
Allogeneic Stem Cell Transplantation for Aplastic Anemia
Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis  Jason.
Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes 
HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category  Ann Woolfrey, Stephanie J.
Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV?  Marie von Lilienfeld-Toal, MD, Maria Gilleece,
A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation  Philippe Armand, Haesook.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.
Eliane Gluckman  Experimental Hematology 
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Rachel B. Salit, H. Joachim Deeg 
Mary Eapen  Biology of Blood and Marrow Transplantation 
Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.
Pure red cell aplasia by Robert T. Means Blood
Suggested algorithm for bone marrow biopsy and skeletal imaging in patients with monoclonal gammopathy of undetermined significance. #Mayo Clinic Risk.
by Lapo Alinari, and Kristie A. Blum
Current Treatment Landscape in MF
Presentation transcript:

Stem cell transplant in MF: it’s time to personalize by Francesco Passamonti Blood Volume 133(20):2118-2120 May 16, 2019 ©2019 by American Society of Hematology

Critical information to personalize management of patients with MF Critical information to personalize management of patients with MF. (Top) Decision flowchart for each patient with MF suitable for SCT. (Bottom) All prognostic models in use with variables and score in parentheses for assessing risk category to each patient. Critical information to personalize management of patients with MF. (Top) Decision flowchart for each patient with MF suitable for SCT. (Bottom) All prognostic models in use with variables and score in parentheses for assessing risk category to each patient. Dynamic International Prognostic Scoring System (DIPSS) categories: low (0); intermediate-1 (1-2), intermediate-2 (3-4), high risk (5-6); Mutation-Enhanced International Prognostic Score System (MIPSS-70) categories: low (0-1); intermediate (2-4), high risk (≥5); Myelofibrosis Secondary Prognostic model (MYSEC-PM) categories: low (<11); intermediate-1 (11-13), intermediate-2 (14-15), high risk (≥16), http://www.mysec-pm.eu; MTSS categories: low (0-2); intermediate (3-4), high (5), very-high risk (6-9). BM, bone marrow; BMF, bone marrow fibrosis; Cont, continuous; C.S., constitutional symptoms; Hb, hemoglobin value; HMR, high-molecular risk; K., Karnofsky; MMU, mismatched unrelated; mut., mutation; PLT, platelet count; P.S., performance status; WBC, white blood cell count. Francesco Passamonti Blood 2019;133:2118-2120 ©2019 by American Society of Hematology